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Information on antiretroviral dosing errors among health
care providers for outpatient human immunodeficiency virus
(HIV)–infected patients is lacking. We evaluated factors as-
sociated with nucleoside reverse-transcriptase inhibitor dos-
ing errors in a university-based HIV clinic using an electronic
medical record. Overall, older age, minority race or ethnicity,
and didanosine use were related to such errors. Impaired
renal function was more common in older patients and racial
or ethnic minorities and, in conjunction with fixed-dose
combination drugs, contributed to the higher rates of errors
in nucleoside reverse-transcriptase inhibitor dosing. Under-
standing the factors related to nucleoside reverse-transcrip-
tase inhibitor dosing errors is an important step in the build-
ing of preventive tools.
Antiretroviral prescribing errors can contribute to HIV treat-
ment failure, the development of drug resistance, and increased
toxicity when drugs are inappropriately dosed [1]. The use of
an increasingly complex arsenal of drugs by non–HIV-infection
specialists is postulated to contribute to antiretroviral dosing
errors among HIV-infected inpatients [2–6], but little is known
about the frequency of and factors related to dosing errors by
specialists treating outpatients, particularly with newer cofor-
mulated nucleoside reverse-transcriptase inhibitors (NRTIs).
The advent of fixed-dose NRTI combination tablets with
similar efficacy and a lower pill burden have led to the increased
selection of these agents as dual-NRTI backbones for contem-
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porary HIV therapy [7–9]. Combination NRTI preparations
that are dose-adjusted for renally impaired patients are not
currently available, creating the potential for dosing errors.
The present study assessed the frequency of and factors re-
lated to NRTI dosing errors in a university-based outpatient
HIV clinic. Medications were prescribed by HIV-infection spe-
cialists using a locally programmed electronic medical record
(EMR). We hypothesized that dosing errors would be more
common among renally impaired patients and that the use of
combination NRTIs would increase the risk for dosing errors
in such patients.
Methods. The University of Alabama at Birmingham 1917
HIV/AIDS Clinic (Birmingham, AL) currently cares for 11400
HIV-infected patients. In 2004, the clinic deployed its own
client-server–based point-of-care EMR, which was developed
within the clinic to its own specifications. This system allows
for real-time collection of medication, laboratory, clinical, and
health care use data. The EMR contains readily accessible drug
prescription information supplied by the Clinical Pharmacol-
ogy Database from Gold Standard Multimedia. This infor-
mation is used to process drug-drug interactions for new pre-
scriptions as they are added to the EMR by primary health care
providers. Health care providers have access to data needed to
calculate creatinine clearance (using the Cockcroft-Gault equa-
tion) in the EMR, but at present, the EMR neither performs
this calculation nor offers dosing recommendations [10].
Most uninsured patients fill antiretroviral prescriptions at
our clinic pharmacy; other patients often choose to use outside
pharmacies. University of Alabama at Birmingham 1917 Clinic
pharmacists do not have access to renal function and weight
data when filling prescriptions and, therefore, are not able to
evaluate dosing errors in antiretroviral prescriptions on the
basis of these parameters.
All new NRTI medication records added to the EMR system
from 1 August 2004 through 15 September 2006 were identified.
NRTIs were included in the analysis if data needed to calculate
creatinine clearance by the Cockcroft-Gault equation were
available to providers prior to the date of prescription. Only
erroneous NRTI prescriptions not corrected within 24 h of the
original entry in the EMR were included; errors corrected in
less time were excluded from the analysis.
Two reviewers independently examined all NRTI prescrip-
tions for dosing errors. Four categories of NRTI dosing errors
were defined: (1) weight errors, defined as failure to adjust the
dosage to a patient’s weight; (2) renal errors, defined as failure
to adjust the dosage to the patients’ creatinine clearance value
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Table 1. Factors associated with dosing errors for 907 new nucleoside reverse-tran-
scriptase inhibitor (NRTI) prescriptions at the University of Alabama at Birmingham
1917 HIV/AIDS Clinic, August 2004–September 2006.
Variable
OR (95% CI)
Univariate
analysis
Multivariable
analysis
Drug administered, didanosine vs. other NRTI 10.11 (5.50–18.61) 11.51 (5.99–22.08)
Age, per 10 years 1.50 (1.13–1.98) 1.75 (1.28–2.38)
Sex, female vs. male 1.38 (0.75–2.53) 1.16 (0.58–2.31)
Health care provider, physicians vs.
nurse practitioners/others 1.33 (0.76–2.33) 1.58 (0.85–2.94)
Race, black/other vs. white 2.68 (1.45–4.94) 2.69 (1.37–5.26)
NOTE. Analyses was performed using generalized estimated equations to account for nesting of
multiple prescriptions within individual patients.
(calculated using the Cockcroft-Gault equation); (3) failure to
adjust the didanosine dosage when used in conjunction with
tenofovir; and (4) the use of nonstandard dosages (i.e., dosages
not approved for use in the United States).
The primary outcome measure, presence of an NRTI dosing
error, was a dichotomous measure. Study variables were eval-
uated using descriptive statistics to evaluate distributions and
to ensure that the assumptions of statistical tests were met.
Univariate and multivariable logistic regression models were
used to evaluate the relationships between dosing errors among
all NRTI prescriptions and demographic factors (age, sex, and
race), provider type (physicians, including infectious-diseases
fellows and attendings, vs. nurse practitioners), and the use of
didanosine. To estimate the mediating effect of renal impair-
ment (defined as a creatinine clearance !60 mL/min) on the
statistically significant variables, an additional multivariable lo-
gistic regression model containing renal impairment was fit.
All analyses were performed at the level of the prescription
and used generalized estimating equations for binary outcomes
with a logit link for the analysis of correlated data to account
for the nesting of multiple NRTI prescriptions within individual
patients [11]. Using an exchangeable correlation structure gen-
eralized estimating equation provided standard errors adjusted
for multiple prescriptions per patient (907 new NRTI prescrip-
tions among 603 patients). The use of generalized estimating
equations addresses problems associated with clustered data
and yields consistent parameter estimates and robust standard
errors [12].
A subanalysis involving patients with impaired renal function
(creatinine clearance, !60 mL/min, according to Cockcroft-
Gault equation) evaluated relationships between dosing errors
and coformulated NRTIs, demographic factors (i.e., age, sex,
and race), and provider type (physicians vs. nurse practitioners)
using univariate and multivariable generalized estimating equa-
tion logistic regression. All statistical analyses were performed
using SAS software, version 9.1.3 (SAS Institute).
Results. During the study period, 922 NRTI prescription
records were generated. Fifteen records were excluded (14 for
discontinuation within !24 h and 1 for adefovir), and 907 NRTI
records for 603 patients were analyzed. Patient characteristics
were as follows: median age, 40 years; white race, 51%; male
sex, 76%; uninsured, 28%; cared for by nurse practitioners,
49%; impaired renal function (creatinine clearance, !60 mL/
min), 12%; median CD4 cell count, 256 cells/mm3; and median
viral load, 4.0 1og10 copies/mL (CD4 and viral load values ob-
tained 180 days from study initiation).
Overall, 53 (6%) of a total of 907 NRTI prescriptions and
41 (31%) of 132 prescriptions in renally impaired patients were
dosed incorrectly. Among the 53 prescriptions overall that were
dosed incorrectly, several had multiple flaws, and 63 total errors
were detected. Among flawed prescriptions in the overall group,
renal dosing errors were most common (40 [75%] of 53 errors).
The NRTI most frequently misdosed was didanosine; 22 (28%)
of 78 didanosine prescriptions were misdosed. Clinical con-
sequences of incorrect dosing were observed in only 2 patients,
including 1 patient with acute renal failure (which subsequently
reversed) and 1 patient with nonfatal lactic acidosis syndrome.
In generalized estimating equation–adjusted multivariable lo-
gistic regression analysis, didanosine use (OR, 11.51; 95% CI,
5.99–22.1), advancing age (OR, 1.75 per 10 years; 95% CI, 1.28–
2.38 per 10 years), and minority race or ethnicity (OR, 2.69;
95% CI, 1.37–5.26) were associated with dosing errors (table 1).
We postulated that the increased risk of dosing errors seen
in older patients and racial or ethnic minorities was associated
with worse renal function in these groups [13]. To evaluate this
hypothesis, renal dysfunction (creatinine clearance, !60 mL/
min) was added to the multivariable model. Using this model,
the effects of age and race or ethnicity were attenuated and
were no longer statistically significant, supporting our postulate
(data not shown).
To test whether dosing errors were associated with the use
of coformulated NRTIs in patients with renal impairment (cre-
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atinine clearance, !60 mL/min), a subanalysis of both single
and coformulated NRTI agents was performed. In multivariable
analysis, coformulated NRTIs (OR, 3.73; 95% CI, 1.46–9.48)
and race or ethnicity (OR, 8.12; 95% CI, 1.96–33.66) were
associated with dosing errors.
Discussion. This study of NRTI prescriptions at a univer-
sity-based HIV clinic using an EMR found errors in 6% of
prescriptions overall and in 31% of prescriptions for patients
with renal impairment. Previous studies, conducted among
HIV-infected inpatients, have identified nonstandard dosing
(i.e., overdosing, underdosing, or incorrect frequency of dos-
ing) as the most common error type and have identified la-
mivudine as the NRTI most frequently associated with pre-
scribing errors [2–6], compared with the findings in our study
that a lack of dose adjustment for patients with renal impair-
ment was the most common error and that didanosine was the
NRTI most frequently associated with prescribing errors. Be-
cause didanosine was the only NRTI for which all 4 defined
error types could occur, the complexity of didanosine dosing,
relative to dosing with other NRTIs, might explain the higher
risk of errors associated with this drug.
Use of coformulated NRTIs has increased over time, because
they are associated with a reduced pill burden and provide the
ability to simplify a patient’s drug regimen. Compared with
individual dosing of their constituent drugs, dosing of cofor-
mulated NRTIs was associated with nearly a 4-fold risk of dos-
ing errors among renally impaired patients. Because formula-
tions of coformulated NRTIs for patients with impaired renal
function are not currently available, this is an important finding
for providers prescribing these agents in clinical practice. Renal
function should be monitored carefully, and caution must be
exercised in treating patients with impaired renal function.
Incorrectly dosed antiretrovirals may lead to increased tox-
icity and accentuated adverse effects, which contribute to non-
compliance, drug resistance, virologic failure, and clinical de-
terioration [1, 2, 4, 6, 14]. In our study, 2 patients experienced
clinical adverse outcomes possibly related to incorrect dosing.
In addition, prescription errors can lead to increased costs of
care. Avoidance of the dosing errors observed in this study
would have resulted in savings of $80,884 from drug costs alone
had accurately dosed NRTIs been used for the same duration,
without taking into account the costs associated with treatment
of any clinical sequelae of improper dosing.
These findings should be interpreted with respect to the lim-
itations of this study. This study was conducted in a single
academically affiliated HIV clinic; therefore, these finding might
not be generalizable to other clinical settings or regions of the
country. It is important to note that we detected dosing errors
as recorded by providers in the EMR, but we cannot confirm
that all erroneous prescriptions were filled by patients. We were
unable to link dosing errors to all adverse outcomes in the
current study, although a future evaluation of the sequelae of
dosing errors is planned.
Overall, our findings highlight the importance of renal im-
pairment in NRTI dosing errors and identify the demographic
groups at greatest risk for dosing errors. Coformulated NRTIs
must be used carefully among renally impaired patients. Soft-
ware that generates NRTI dosing recommendations on the basis
of renal function, weight, coadministered drugs, and standard
dosage recommendations may greatly reduce NRTI dosing er-
rors in the health care system. Such software is currently under
development at the University of Alabama at Birmingham 1917
HIV/AIDS Clinic.
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